Clinical Trials Logo

Clinical Trial Summary

A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04225429
Study type Expanded Access
Source Ipsen
Contact
Status No longer available
Phase

See also
  Status Clinical Trial Phase
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT05286801 - Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Phase 1/Phase 2
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Active, not recruiting NCT03069378 - A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Phase 2
Completed NCT03837678 - Epithelioid Sarcoma Natural History Study
Active, not recruiting NCT02180867 - Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Phase 2/Phase 3
Recruiting NCT04008238 - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients N/A
Completed NCT02584309 - Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Not yet recruiting NCT06277154 - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma Phase 2
Completed NCT02601950 - A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Phase 2
Completed NCT03190174 - Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Phase 1/Phase 2
Recruiting NCT03099681 - An Observational Study on Epithelioid Sarcoma
Recruiting NCT04416568 - Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Phase 2
Recruiting NCT05407441 - Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Phase 1/Phase 2
Recruiting NCT03967834 - Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group N/A